Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity

Cornelis Jan De Groot; Christine Poitou Bernert; Muriel Coupaye; Karine Clement; Stavroula A. Paschou; Evangelia Charmandari; Christina Kanaka-Gantenbein; Martin Wabitsch; Emilie P. Buddingh; Barbara Nieuwenhuijsen; Ljiljana Marina; Gudmundur Johannsson; E. L.T. Van Den Akker

doi:10.1007/s12020-021-02619-y

Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity

Cornelis Jan De Groot^*
, Christine Poitou Bernert
, Muriel Coupaye
, Karine Clement
, Stavroula A. Paschou
, Evangelia Charmandari
, Christina Kanaka-Gantenbein
, Martin Wabitsch
, Emilie P. Buddingh
, Barbara Nieuwenhuijsen
, Ljiljana Marina
, Gudmundur Johannsson
, E. L.T. Van Den Akker

^*Corresponding author for this work

Pediatrics

Hôpital La Pitié-Salpêtrière
Sorbonne Université
Assistance publique – Hôpitaux de Paris
National and Kapodistrian University of Athens
University of Athens
Biomedical Research Foundation Academy of Athens
University Hospital Ulm
Leiden University Medical Centre
University Medical Centre Utrecht
University of Belgrade
Sahlgrenska University Hospital

Research output: Contribution to journal › Review article › Academic › peer-review

6 Citations (Scopus)

44 Downloads (Pure)

Abstract

This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.

Original language	English
Pages (from-to)	653-662
Number of pages	10
Journal	Endocrine
Volume	71
Issue number	3
DOIs	https://doi.org/10.1007/s12020-021-02619-y
Publication status	Published - Mar 2021

Bibliographical note

Funding Information:
This RareEndoERN Growth & Genetic Obesity COVID-19 Study Group has been made possible by the European Reference Network on Rare Endocrine Conditions (Endo-ERN), Main Thematic Group 5 (MTG5); The European Society Endocrinology (ESE) and European Society for Paediatric Endocrinology (ESPE). We would like to specifically acknowledge, Alberto Pereira and Olaf Hiort coordinators Rare Endo-ERN and Simona Glassberg (chair) and Faisal Ahmed and Vicki Di Guisto (members) of the ESE Research Development Committee for their support. C.J.D.G. is the first author of this manuscript. C.P.B. is contributed to the manuscript on the subject of PWS, genetic obesity and obesity and risk of COVID. M.C. is contributed to the manuscript on the subject of PWS, + obesity and covid risk. S.A.P. is contributed to the manuscript with input on the structure and on the subject of COVID19. E.C. is contributed to the manuscript on the subject of adrenal insufficiency; review and comment on manuscript. C.K.G. is contributed to the manuscript by review and comments. M.W. is contributed to this manuscript on the subject of obesity and COVID risk. E.P.B. is revised the paragraphs that discuss immune response, vaccination, viral shedding. B.N. is contributed with a literature search and writing a literature review for her Master thesis biomedical science and critically reviewed the final manuscript. G.J. is contributed by coordination of the COVID19 Study Group and review and comment on manuscript. E.L.T.V.D.A. set up the structure, supervised C.J.D.G. and B.N. and reviewed the first drafts; final review.

Publisher Copyright:
© 2021, The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s12020-021-02619-yLicence: CC BY

Clinical management of patients with genetic obesity during COVID-19 pandemicFinal published version, 602 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity'. Together they form a unique fingerprint.

Cite this

De Groot, C. J., Poitou Bernert, C., Coupaye, M., Clement, K., Paschou, S. A., Charmandari, E., Kanaka-Gantenbein, C., Wabitsch, M., Buddingh, E. P., Nieuwenhuijsen, B., Marina, L., Johannsson, G., & Van Den Akker, E. L. T. (2021). Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity. Endocrine, 71(3), 653-662. https://doi.org/10.1007/s12020-021-02619-y

@article{46628325b74748c4b7bd9b189d0d1242,

title = "Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth \& Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity",

abstract = "This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.",

author = "\{De Groot\}, \{Cornelis Jan\} and \{Poitou Bernert\}, Christine and Muriel Coupaye and Karine Clement and Paschou, \{Stavroula A.\} and Evangelia Charmandari and Christina Kanaka-Gantenbein and Martin Wabitsch and Buddingh, \{Emilie P.\} and Barbara Nieuwenhuijsen and Ljiljana Marina and Gudmundur Johannsson and \{Van Den Akker\}, \{E. L.T.\}",

note = "Funding Information: This RareEndoERN Growth \& Genetic Obesity COVID-19 Study Group has been made possible by the European Reference Network on Rare Endocrine Conditions (Endo-ERN), Main Thematic Group 5 (MTG5); The European Society Endocrinology (ESE) and European Society for Paediatric Endocrinology (ESPE). We would like to specifically acknowledge, Alberto Pereira and Olaf Hiort coordinators Rare Endo-ERN and Simona Glassberg (chair) and Faisal Ahmed and Vicki Di Guisto (members) of the ESE Research Development Committee for their support. C.J.D.G. is the first author of this manuscript. C.P.B. is contributed to the manuscript on the subject of PWS, genetic obesity and obesity and risk of COVID. M.C. is contributed to the manuscript on the subject of PWS, + obesity and covid risk. S.A.P. is contributed to the manuscript with input on the structure and on the subject of COVID19. E.C. is contributed to the manuscript on the subject of adrenal insufficiency; review and comment on manuscript. C.K.G. is contributed to the manuscript by review and comments. M.W. is contributed to this manuscript on the subject of obesity and COVID risk. E.P.B. is revised the paragraphs that discuss immune response, vaccination, viral shedding. B.N. is contributed with a literature search and writing a literature review for her Master thesis biomedical science and critically reviewed the final manuscript. G.J. is contributed by coordination of the COVID19 Study Group and review and comment on manuscript. E.L.T.V.D.A. set up the structure, supervised C.J.D.G. and B.N. and reviewed the first drafts; final review. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = mar,

doi = "10.1007/s12020-021-02619-y",

language = "English",

volume = "71",

pages = "653--662",

journal = "Endocrine",

issn = "1355-008X",

publisher = "Springer",

number = "3",

}

De Groot, CJ, Poitou Bernert, C, Coupaye, M, Clement, K, Paschou, SA, Charmandari, E, Kanaka-Gantenbein, C, Wabitsch, M, Buddingh, EP, Nieuwenhuijsen, B, Marina, L, Johannsson, G & Van Den Akker, ELT 2021, 'Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity', Endocrine, vol. 71, no. 3, pp. 653-662. https://doi.org/10.1007/s12020-021-02619-y

Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity. / De Groot, Cornelis Jan; Poitou Bernert, Christine; Coupaye, Muriel et al.
In: Endocrine, Vol. 71, No. 3, 03.2021, p. 653-662.

Research output: Contribution to journal › Review article › Academic › peer-review

TY - JOUR

T1 - Clinical management of patients with genetic obesity during COVID-19 pandemic

T2 - position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity

AU - De Groot, Cornelis Jan

AU - Poitou Bernert, Christine

AU - Coupaye, Muriel

AU - Clement, Karine

AU - Paschou, Stavroula A.

AU - Charmandari, Evangelia

AU - Kanaka-Gantenbein, Christina

AU - Wabitsch, Martin

AU - Buddingh, Emilie P.

AU - Nieuwenhuijsen, Barbara

AU - Marina, Ljiljana

AU - Johannsson, Gudmundur

AU - Van Den Akker, E. L.T.

N1 - Funding Information: This RareEndoERN Growth & Genetic Obesity COVID-19 Study Group has been made possible by the European Reference Network on Rare Endocrine Conditions (Endo-ERN), Main Thematic Group 5 (MTG5); The European Society Endocrinology (ESE) and European Society for Paediatric Endocrinology (ESPE). We would like to specifically acknowledge, Alberto Pereira and Olaf Hiort coordinators Rare Endo-ERN and Simona Glassberg (chair) and Faisal Ahmed and Vicki Di Guisto (members) of the ESE Research Development Committee for their support. C.J.D.G. is the first author of this manuscript. C.P.B. is contributed to the manuscript on the subject of PWS, genetic obesity and obesity and risk of COVID. M.C. is contributed to the manuscript on the subject of PWS, + obesity and covid risk. S.A.P. is contributed to the manuscript with input on the structure and on the subject of COVID19. E.C. is contributed to the manuscript on the subject of adrenal insufficiency; review and comment on manuscript. C.K.G. is contributed to the manuscript by review and comments. M.W. is contributed to this manuscript on the subject of obesity and COVID risk. E.P.B. is revised the paragraphs that discuss immune response, vaccination, viral shedding. B.N. is contributed with a literature search and writing a literature review for her Master thesis biomedical science and critically reviewed the final manuscript. G.J. is contributed by coordination of the COVID19 Study Group and review and comment on manuscript. E.L.T.V.D.A. set up the structure, supervised C.J.D.G. and B.N. and reviewed the first drafts; final review. Publisher Copyright: © 2021, The Author(s).

PY - 2021/3

Y1 - 2021/3

N2 - This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.

AB - This article aims to provide guidance on prevention and treatment of COVID-19 in patients with genetic obesity. Key principals of the management of patients with genetic obesity during COVID-19 pandemic for patients that have contracted COVID-19 are to be aware of: possible adrenal insufficiency (e.g., POMC deficiency, PWS); a more severe course in patients with concomitant immunodeficiency (e.g., LEP and LEPR deficiency), although defective leptin signalling could also be protective against the pro-inflammatory phenotype of COVID-19; disease severity being masked by insufficient awareness of symptoms in syndromic obesity patients with intellectual deficit (in particular PWS); to adjust medication dose to increased body size, preferably use dosing in m2; the high risk of malnutrition in patients with Sars-Cov2 infection, even in case of obesity. Key principals of the obesity management during the pandemic are to strive for optimal obesity management and a healthy lifestyle within the possibilities of the regulations to prevent weight (re)gain and to address anxiety within consultations, since prevalence of anxiety for COVID-19 is underestimated.

UR - https://www.scopus.com/pages/publications/85099963034

U2 - 10.1007/s12020-021-02619-y

DO - 10.1007/s12020-021-02619-y

M3 - Review article

C2 - 33512658

AN - SCOPUS:85099963034

SN - 1355-008X

VL - 71

SP - 653

EP - 662

JO - Endocrine

JF - Endocrine

IS - 3

ER -

Clinical management of patients with genetic obesity during COVID-19 pandemic: position paper of the ESE Growth & Genetic Obesity COVID-19 Study Group and Rare Endo-ERN main thematic group on Growth and Obesity

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this